The topical treatment Vyjuvek got the FDA’s greenlight, making it the first redosable gene therapy and the first therapeutic for the rare skin disease dystrophic epidermolysis bullosa.
https://www.pharmalive.com/wp-content/uploads/2022/02/FDA-Investigating-Possible-Death-Risk-Linked-to-TG-Therapeutics-Lymphoma-Drug-BioSpace-2-7-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-05-22 09:25:332023-05-22 09:25:33Krystal gets first FDA approval for redosable gene therapy, rare skin disease
